🔍
☰
Applications are currently being accepted for the Pfizer Grant for Generic JAK Inhibitors in Rheumatology 2026. Interested applicants are encouraged to click here to learn more about this opportunity and apply for it.
The opportunity is designed to help healthcare professionals better understand how treatment pathways may change as generic JAK inhibitors enter the U.S. market in 2026, and how current evidence can inform safe, effective, and data-driven patient care.
The grant provides:
This funding opportunity is intended for organizations, not individuals.
Eligible Applicants
Examples of eligible applicants include:
Healthcare institutions
Professional medical societies
Medical education companies
Other organizations involved in:
Healthcare education
Continuing medical education (CME/CE)
Quality improvement
Healthcare performance improvement
Core Eligibility Requirements
To be eligible, the applicant organization should:
Play a central role in the proposed project
Be legally able to receive funding directly from Pfizer Inc.
Be responsible for project delivery and oversight
Have the organizational capacity to implement an independent educational initiative
Apply for Pfizer Grant for Generic JAK Inhibitors in Rheumatology
